MA40481A - Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante - Google Patents

Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante

Info

Publication number
MA40481A
MA40481A MA040481A MA40481A MA40481A MA 40481 A MA40481 A MA 40481A MA 040481 A MA040481 A MA 040481A MA 40481 A MA40481 A MA 40481A MA 40481 A MA40481 A MA 40481A
Authority
MA
Morocco
Prior art keywords
pyridin
isocitrate dehydrogenase
dehydrogenase inhibitors
mutant isocitrate
quinolinone derivatives
Prior art date
Application number
MA040481A
Other languages
English (en)
Inventor
Susan Ashwell
Ann-Marie Campbell
Justin Andrew Caravella
R Bruce Diebold
Anna Ericsson
Gary Gustafson
Jr David R Lancia
Jian Lin
Wei Lu
Zhongguo Wang
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MA40481A publication Critical patent/MA40481A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne des inhibiteurs de protéines d'isocitrate déshydrogénase mutantes (mt-idh) ayant une activité néomorphe, utiles pour traiter les troubles liés à la prolifération cellulaire et les cancers, de formule : (i) où a, u, w1, w2, w3, r1-r6, et r9 sont tels que décrits dans la présente.
MA040481A 2014-09-19 2015-09-18 Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante MA40481A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US201562150812P 2015-04-21 2015-04-21

Publications (1)

Publication Number Publication Date
MA40481A true MA40481A (fr) 2017-07-26

Family

ID=54291606

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053352A MA53352A (fr) 2014-09-19 2015-09-18 Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA040481A MA40481A (fr) 2014-09-19 2015-09-18 Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053352A MA53352A (fr) 2014-09-19 2015-09-18 Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase

Country Status (37)

Country Link
US (8) US9834539B2 (fr)
EP (4) EP4257131A3 (fr)
JP (1) JP6648115B2 (fr)
KR (1) KR102209667B1 (fr)
CN (3) CN107001328B (fr)
AU (3) AU2015317329B2 (fr)
BR (1) BR112017005238B1 (fr)
CA (1) CA2961817C (fr)
CL (1) CL2017000658A1 (fr)
CO (1) CO2017003241A2 (fr)
CY (2) CY1121149T1 (fr)
DK (2) DK3447050T3 (fr)
EA (1) EA034336B1 (fr)
EC (1) ECSP17022933A (fr)
ES (3) ES2790640T3 (fr)
FI (1) FI3733662T3 (fr)
HR (1) HRP20200666T1 (fr)
HU (2) HUE062424T2 (fr)
IL (3) IL292608B2 (fr)
LT (2) LT3447050T (fr)
MA (2) MA53352A (fr)
ME (1) ME03776B (fr)
MX (2) MX2017003404A (fr)
MY (2) MY176250A (fr)
NZ (1) NZ730373A (fr)
PE (1) PE20171056A1 (fr)
PH (1) PH12017500517B1 (fr)
PL (3) PL3194376T3 (fr)
PT (3) PT3733662T (fr)
RS (2) RS60140B1 (fr)
SA (1) SA517381129B1 (fr)
SG (1) SG11201702194SA (fr)
SI (2) SI3194376T1 (fr)
SM (2) SMT202000212T1 (fr)
TW (1) TWI686390B (fr)
WO (1) WO2016044789A1 (fr)
ZA (3) ZA201702127B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
EP3064595B1 (fr) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Procédés pour des troubles liés à la prolifération cellulaire
EP3102568B1 (fr) 2014-02-06 2018-06-27 Heptares Therapeutics Limited Composés aza bicycliques en tant qu'agonistes du récepteur muscarinique m1
KR102209667B1 (ko) * 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
MX2017003664A (es) 2014-09-19 2017-07-13 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1.
EP3201185B1 (fr) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Dérivé de pyridinylquinolinone en tant qu'inhibiteurs de l'isocitrate déshydrogénase mutante
AU2015317321B2 (en) * 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
CN107428690B (zh) * 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2016171755A1 (fr) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Dérivés de phénylquinoléinone en tant qu'inhibiteurs de l'isocitrate déshydrogénase mutante
HUE059057T2 (hu) 2017-05-04 2022-10-28 Bayer Cropscience Ag 2-{[2-(feniloximetil)piridin-5-il]oxi}-etánamin-származékok és rokon vegyületek mint peszticidek, például növényvédelemre
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2020232381A1 (fr) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. Inhibition de l'isocitrate déshydrogénase 1 mutante (midh-1)
US11738018B2 (en) 2018-05-16 2023-08-29 FORMA Therapeuetics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (fr) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Formes solides de ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl) éthyl)amino)-1-méthyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US20210196701A1 (en) * 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11497743B2 (en) 2018-05-16 2022-11-15 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
AU2003243497A1 (en) 2002-06-12 2003-12-31 Millennium Pharmaceuticals, Inc. Antagonists of melanin concentrating hormone receptor
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
RU2284325C2 (ru) * 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2005095382A1 (fr) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Agent anti tumoral
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CA2657287A1 (fr) * 2006-07-17 2008-01-24 Merck & Co., Inc. Composes de 1-hydroxy naphtyridine en tant qu'agents anti-vih
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
EP2152676B1 (fr) 2007-04-30 2013-04-03 ProMetic BioSciences Inc. Dérivés de triazine, compositions contenant de tels dérivés et procédés de traitement du cancer et de maladies auto-immunes par ces dérivés
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
EP2509600B1 (fr) * 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh
WO2012006104A2 (fr) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Composés et procédés destinés au traitement d'une infection par la tuberculose
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
WO2012129562A2 (fr) 2011-03-24 2012-09-27 The Scripps Research Institute Composés et procédés pour l'induction de la chondrogenèse
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
AU2012313888B2 (en) 2011-09-27 2016-03-31 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9353121B2 (en) 2011-12-21 2016-05-31 The Regents Of The University Of Colorado, A Body Corporate Anti-cancer compounds targeting Ral GTPases and methods of using the same
LT2800743T (lt) 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
BR112015022483A2 (pt) * 2013-03-14 2017-07-18 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
BR112016018604A2 (pt) 2014-02-11 2017-08-08 Bayer Pharma AG Benzimidazol-2-aminas como inibidores de midh1
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317321B2 (en) 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
EP3201185B1 (fr) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Dérivé de pyridinylquinolinone en tant qu'inhibiteurs de l'isocitrate déshydrogénase mutante
KR102209667B1 (ko) * 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
CN107428690B (zh) 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
WO2016171755A1 (fr) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Dérivés de phénylquinoléinone en tant qu'inhibiteurs de l'isocitrate déshydrogénase mutante
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
JP6473270B2 (ja) 2015-07-27 2019-02-20 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用
WO2017146795A1 (fr) 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
ES2814290T3 (es) 2016-06-06 2021-03-26 Lilly Co Eli Inhibidores de IDH1 mutante
WO2017223202A1 (fr) 2016-06-22 2017-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisations de dérivés de thiazole en tant qu'inhibiteurs mutants d'idh1 pour le traitement du cancer
PH12019501328B1 (en) 2016-12-16 2023-05-12 Lilly Co Eli 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors

Also Published As

Publication number Publication date
CN107001328A (zh) 2017-08-01
AU2021215141B2 (en) 2023-10-19
CN111909130A (zh) 2020-11-10
WO2016044789A1 (fr) 2016-03-24
CN117695280A (zh) 2024-03-15
EP3194376B1 (fr) 2018-10-24
US20200223822A1 (en) 2020-07-16
DK3194376T3 (en) 2019-01-21
TWI686390B (zh) 2020-03-01
PL3194376T3 (pl) 2019-05-31
SMT201900018T1 (it) 2019-02-28
DK3447050T3 (da) 2020-03-09
EP3194376A1 (fr) 2017-07-26
PE20171056A1 (es) 2017-07-21
SA517381129B1 (ar) 2021-04-26
MA53352A (fr) 2021-09-15
NZ730373A (en) 2019-11-29
CY1122865T1 (el) 2021-05-05
EP3733662A1 (fr) 2020-11-04
SI3447050T1 (sl) 2020-08-31
MX385512B (es) 2025-03-18
CA2961817C (fr) 2024-03-12
IL292608A (en) 2022-07-01
CN111909130B (zh) 2023-10-31
PT3733662T (pt) 2023-08-18
AU2019283765A1 (en) 2020-01-16
BR112017005238A2 (pt) 2017-12-19
NZ758641A (en) 2023-12-22
EP3733662B1 (fr) 2023-06-07
PH12017500517B1 (en) 2022-08-03
ES2704897T3 (es) 2019-03-20
ZA201902446B (en) 2023-12-20
EP4257131A2 (fr) 2023-10-11
JP2017528487A (ja) 2017-09-28
AU2021215141A1 (en) 2021-09-02
MY197533A (en) 2023-06-21
CA2961817A1 (fr) 2016-03-24
IL292608B2 (en) 2024-10-01
EA201790657A1 (ru) 2017-08-31
ES2790640T3 (es) 2020-10-28
US20240150319A1 (en) 2024-05-09
SMT202000212T1 (it) 2020-05-08
LT3447050T (lt) 2020-05-11
EP3447050B1 (fr) 2020-02-19
BR112017005238B1 (pt) 2023-01-17
AU2015317329A1 (en) 2017-04-27
SG11201702194SA (en) 2017-04-27
IL251163B (en) 2021-05-31
LT3194376T (lt) 2019-02-25
MX2017003404A (es) 2017-07-28
PL3447050T3 (pl) 2020-07-27
ZA202304409B (en) 2024-08-28
ZA201702127B (en) 2019-06-26
ECSP17022933A (es) 2017-08-31
US20170174658A1 (en) 2017-06-22
US10550098B2 (en) 2020-02-04
US10414752B2 (en) 2019-09-17
SI3194376T1 (sl) 2019-03-29
TW201617335A (zh) 2016-05-16
RS60140B1 (sr) 2020-05-29
KR102209667B1 (ko) 2021-01-29
EP3447050A1 (fr) 2019-02-27
PL3733662T3 (pl) 2024-01-22
CL2017000658A1 (es) 2017-12-22
IL282363B (en) 2022-06-01
AU2015317329B2 (en) 2019-10-31
US20160083366A1 (en) 2016-03-24
US20230125739A1 (en) 2023-04-27
HUE041460T2 (hu) 2019-05-28
US20180312487A1 (en) 2018-11-01
CN107001328B (zh) 2020-06-05
HUE062424T2 (hu) 2023-11-28
CO2017003241A2 (es) 2017-09-20
IL292608B1 (en) 2024-06-01
JP6648115B2 (ja) 2020-02-14
KR20170063742A (ko) 2017-06-08
US20210078973A1 (en) 2021-03-18
ME03776B (fr) 2021-04-20
US20190263778A1 (en) 2019-08-29
EA201790657A8 (ru) 2018-02-28
EP4257131A3 (fr) 2024-01-10
US11498913B2 (en) 2022-11-15
MY176250A (en) 2020-07-24
RS58184B1 (sr) 2019-03-29
US9834539B2 (en) 2017-12-05
US12275715B2 (en) 2025-04-15
EA034336B1 (ru) 2020-01-29
ES2953347T3 (es) 2023-11-10
AU2019283765B2 (en) 2021-05-13
US10889567B2 (en) 2021-01-12
CY1121149T1 (el) 2020-05-29
MX2019013203A (es) 2020-01-20
IL251163A0 (en) 2017-04-30
FI3733662T3 (fi) 2023-08-09
PH12017500517A1 (en) 2017-08-07
PT3447050T (pt) 2020-09-17
IL282363A (en) 2021-06-30
HRP20200666T1 (hr) 2020-07-24
PT3194376T (pt) 2019-02-04

Similar Documents

Publication Publication Date Title
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA202092636A1 (ru) Способ синтеза 2-гидрокси-6-((2-(1-изопропил-1h-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
EA201792047A1 (ru) Новые соединения
EA201690199A1 (ru) Лекарственное средство для лечения неалкогольной жировой болезни печени
EA201790657A1 (ru) Хинолиноновые производные пиридин-2(1h)-она как ингибиторы мутантной изоцитратдегидрогеназы
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EP3778605A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
TN2018000035A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
MA40993A (fr) Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA38250B1 (fr) Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
BR112023001557A2 (pt) Inibidores de raf bicíclicos fundidos e métodos para uso dos mesmos